Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079456 · ClinicalTrials.gov registry record · Phase 2
Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00079456: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00079456 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00079456, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase II trial is studying how well temsirolimus works in treating patients with relapsed or refractory multiple myeloma. Drugs used in chemotherapy such as temsirolimus work in different ways to stop cancer cells from dividing so they stop growing or die.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079456
The ClinicalTrials.gov registry entry for NCT00079456 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00079456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079456 about?
NCT00079456 is a clinical study titled "Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma". This phase II trial is studying how well temsirolimus works in treating patients with relapsed or refractory multiple myeloma. Drugs used in chemotherapy such as temsirolimus work in different ways to stop cancer cells from dividing so they stop growing or die.
What is the current status of trial NCT00079456?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-02.
What interventions are being tested in trial NCT00079456?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00079456?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.